Key result
Body weight-walking distance product correlates more strongly with VO2 on-kinetics than distance alone in CAD.
Why the study?
Anthropometric differences can confound or misestimate functional capacity assessed by the 6-minute walk test, highlighting the need for new parameters.
Does the body weight-walking distance product better predict VO2 on-kinetics compared to the standard 6-minute walk test distance in patients with multivessel coronary artery disease?
Cross-Sectional (n=46)
No
Does the body weight-walking distance product better predict VO2 on-kinetics compared to the standard 6-minute walk test distance in patients with multivessel coronary artery disease?
The body weight-walking distance product is a superior parameter to the standard 6-minute walk distance for estimating VO2 on-kinetics in patients with coronary artery disease.
May support weight-adjusted walk distance for VO2 on-kinetics estimation in CAD; hypothesis-generating and leaves open prospective validation.
The 6-minute walk test is frequently used to assess the functional capacity of the cardiac disease population. Nevertheless, anthropometric differences can confound or misestimate performance, which highlights the need for new parameters. This study aimed to investigate the potential of the body weight-walking distance product (D·W) compared to the 6-minute walk test distance to predict exercise capacity measured by oxygen uptake (VO2) on-kinetics in coronary artery disease (CAD) patients. A cross-sectional study was conducted in a tertiary-care reference institution. Forty-six participants with multivessel CAD with and without left ventricular dysfunction underwent a 6-minute walk test with simultaneous use of mobile telemetric cardiopulmonary monitoring to evaluate VO2 kinetics and other cardiorespiratory responses. The Borg rating of perceived exertion for lower limb discomfort was only correlated with the D·W (P=0.007). The percent predicted and actual distance were only modestly to moderately correlated with VO2 on-kinetics (R2=0.12 and R2=0.29, P<0.05). All the associations of VO2 on-kinetics parameters were improved, showing a stronger correlation to the D·W (R2=0.49, P<0.0001), which also had a larger effect size to identify differences between coronary disease patients compared to distance walked (d=1.32 vs d=0.84). The D·W demonstrated potential to be better than the distance walked in determining VO2 on-kinetics in participants with CAD with and without left ventricular dysfunction.
No takes yet. Share an insight, caveat, or question.
Rocco et al. (2025) conducted a cross-sectional in Coronary artery disease (n=46). Body weight-walking distance product (D·W) vs. 6-minute walk test distance was evaluated on Correlation with VO2 on-kinetics (R2=0.49 vs R2=0.29, p=<0.0001). The body weight-walking distance product showed a stronger correlation with VO2 on-kinetics than distance walked alone (R2=0.49 vs R2=0.29, P<0.0001) in patients with coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: